Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [31] Dosimetric Analysis of Cardiac Substructure Related to Cardiac Safety in Patients With HER2-Positive Breast Cancer Receiving Concurrent Trastuzumab and Adjuvant Radiation Therapy
    Chen, J.
    Cao, L.
    Yang, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S46 - S47
  • [32] Optimizing (neo) adjuvant treatment of HER2-positive breast cancer
    Basho, Reva K.
    McArthur, Heather L.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 13
  • [33] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [34] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [35] Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab.
    Muehlbauer, S.
    Revil, C.
    Leyland-Jones, B.
    Bell, R.
    Baselga, J.
    Marty, M.
    Jones, A.
    Feyereislova, A. F.
    CANCER RESEARCH, 2009, 69 (02) : 389S - 389S
  • [36] Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman, AD
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (04): : 178 - 179
  • [37] Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Andrew D Seidman
    Nature Clinical Practice Oncology, 2006, 3 : 178 - 179
  • [38] Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era
    Nozawa, Kazuki
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Funahashi, Yoriko
    Kogure, Yoshihito
    Kawasaki, Tomonori
    Kato, Aya
    Kitagawa, Chiyoe
    Hayashi, Takako
    Morita, Takako
    Ichihara, Shu
    Saka, Hideo
    Sato, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
    Palmieri, Carlo
    Shah, Deep
    Krell, Jonathan
    Gojis, Ondrej
    Hogben, Katy
    Riddle, Pippa
    Ahmad, Riz
    Tat, Tri
    Fox, Kevin
    Porter, Andrew
    Mahmoud, Sarah
    Kirschke, Stephanie
    Shousha, Sami
    Gudi, Mihir
    Coombes, R. Charles
    Leonard, Robert
    Cleator, Susan
    CLINICAL BREAST CANCER, 2011, 11 (02) : 93 - 102
  • [40] First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO) adjuvant trastuzumab
    Vaglica, M.
    Vaglica, M.
    Lambertini, M.
    Ferreira, A.
    Poggio, F.
    Puglisi, F.
    Sottotetti, F.
    Montemurro, F.
    Poletto, E.
    Pozzi, E.
    Risi, E.
    Lai, A.
    Zanardi, E.
    Sini, V.
    Ziliani, S.
    Minuti, G.
    Mura, S.
    Grasso, D.
    Ferrarini, I.
    Pronzato, P.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 6 - 7
12345